Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties
作者:Xianfeng Li、Suoming Zhang、Yong-Kang Zhang、Yang Liu、Charles Z. Ding、Yasheen Zhou、Jacob J. Plattner、Stephen J. Baker、Wei Bu、Liang Liu、Wieslaw M. Kazmierski、Maosheng Duan、Richard M. Grimes、Lois L. Wright、Gary K. Smith、Richard L. Jarvest、Jing-Jing Ji、Joel P. Cooper、Matthew D. Tallant、Renae M. Crosby、Katrina Creech、Zhi-Jie Ni、Wuxin Zou、Jon Wright
DOI:10.1016/j.bmcl.2011.02.006
日期:2011.4
We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series. (C) 2011 Elsevier Ltd. All rights reserved.
Compounds of formula (I) are as defined in the claims, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.